Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)

Newly enhanced Web site designed as an easy-to-navigate tool for consumers Web site developed with recommendations and feedback from an expert in the field of ADHD


PHILADELPHIA, July 29 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced
today the re-launch of its educational Web site, ADHDSupport.com, designed to
provide families, caregivers, educators and patients with tools and resources
about Attention Deficit Hyperactivity Disorder (ADHD).  The newly enhanced
ADHDSupport.com provides visitors with some information about the evaluation
process and management of the disorder, as well as tools and practical tips to
help patients with ADHD manage their daily activities.


"ADHD is a common psychiatric disorder that can impact the lives of many
people, including patients, caregivers, friends and co-workers.  It has
certainly impacted my own life both personally and professionally," said
Michele Novotni, Ph.D., internationally recognized ADHD expert, former
president and CEO of the national Attention Deficit Disorder Association
(ADDA), psychologist and consultant in the development of ADHDSupport.com.
"Because I have seen the pain of unrealized dreams and untapped potential
first-hand among those with ADHD, I am passionate about providing information
about ADHD in easily accessible formats.  In fact, there are many people who
do not realize that they or their children may have ADHD and many are unaware
of the resources available to help individuals with ADHD find out more about
the disorder.  After reviewing ADHDSupport.com from a clinical and personal
perspective, I can confirm that the Web site is a helpful tool for support and
information about ADHD."


The re-designed ADHDSupport.com provides visitors, especially those who
may be new to ADHD, with an easy-to-navigate road map to help learn about ADHD
and finding daily successes while living with the disorder.  The site offers
information about the recognition, diagnosis and management of the disorder,
assistance with how to identify and select a healthcare professional and what
to expect when meeting with a physician about ADHD.  The Web site will also
feature a symptom tracker to help record ADHD symptoms to be used in follow-up
discussions with the healthcare professional, practical tips on how to get
organized, and stay organized, and the best ways to set and evaluate goals.
Additionally, a teacher discussion guide and homework planner, as well as an
email reminder program -- which allows users to set up various reminders for
themselves or for their children, including for medical appointments,
prescriptions, and social activities -- will be available later this summer in
time for the back-to-school season.


ADHDSupport.com also provides detailed information about events that may
be helpful to people living with ADHD, such as the 13-city mobile screening
event from Shire, known as the "RoADHD Trip," which is designed to help adults
who think they may have ADHD take the first step toward recognizing the
symptoms of the disorder by answering the 6-question World Health Organization
adult ADHD screener.  Additionally, the Web site highlights conferences this
year, such as the 13th annual Attention Deficit Disorder Association (ADDA)
national conference and the 20th annual Children and Adults with Attention
Deficit Hyperactivity Disorder (CHADD) international conference.


"ADHDSupport.com is a useful Web site that contains all sorts of helpful
information about ADHD," said ADHD patient, Heather Jenkins.  "If you have
ADHD like me, or think you know someone who might, ADHDSupport.com is an
excellent place to go for a helpful road map on both information about ADHD
and the steps you can take to help yourself or others find out more about
ADHD."



About ADHD


ADHD is one of the most common psychiatric disorders in children and
adolescents.  Approximately 7.8 percent of all school-aged children, or about
4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at
some point in their lives, according to the U.S. Centers for Disease Control
and Prevention (CDC).  The disorder is also estimated to affect 4.4 percent of
U.S. adults aged 18-44 based on results from the National Comorbidity Survey
Replication, a nationally representative household survey, which used a
lay-administered diagnostic interview to assess a wide range of DSM-IV
disorders.  When this percentage is extrapolated to the full U.S. population,
approximately 9.8 million adults are believed to have ADHD.  ADHD is a
neurobiological disorder that manifests as a persistent pattern of inattention
and/or hyperactivity-impulsivity that is more frequent and severe than is
typically observed in individuals at a comparable level of development.  To be
properly diagnosed with ADHD, a child needs to demonstrate at least six of
nine symptoms of inattention; and/or at least six of nine symptoms of
hyperactivity/impulsivity; the onset of which appears before age 7 years; that
some impairment from the symptoms is present in two or more settings (e.g., at
school and home); that the symptoms continue for at least six months; and that
there is clinically significant impairment in social, academic or occupational
functioning and the symptoms cannot be better explained by another psychiatric
disorder.


Although there is no "cure" for ADHD, there are accepted treatments that
specifically target its symptoms. The most common standard treatments include
educational approaches, psychological or behavioral modification, and
medication.



SHIRE LIMITED


Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit and hyperactivity
disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and
renal diseases. The structure is sufficiently flexible to allow Shire to
target new therapeutic areas to the extent opportunities arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in niche markets with strong intellectual property protection
either in the US or Europe. Shire believes that a carefully selected portfolio
of products with strategically aligned and relatively small-scale sales forces
will deliver strong results.


For further information on Shire, please visit the Company's website:
www.shire.com



"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995


Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of pharmaceutical research, product
development including, but not limited to the successful development of
JUVISTA(R) (Human TGFb3) and veleglucerase alfa (GA-GCB); manufacturing and
commercialization including, but not limited to, the establishment in the
market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and
Hyperactivity Disorder ("ADHD")); the impact of competitive products,
including, but not limited to, the impact of those on Shire's ADHD franchise;
patents, including but not limited to, legal challenges relating to Shire's
ADHD franchise; government regulation and approval, including but not limited
to the expected product approval date of INTUNIV(TM) (guanfacine extended
release) (ADHD); Shire's ability to secure new products for commercialization
and/or development; and other risks and uncertainties detailed from time to
time in Shire's filings with the Securities and Exchange Commission, including
Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.



SOURCE  Shire Limited